Bicillin L-A Is Still in Short Supply: What the FDA’s Lentocilin Import Means for Syphilis Care

Bicillin L-A is still in short supply in the United States, and federal health officials updated their response in March by allowing temporary importation of a similar penicillin product called Lentocilin. For people who may need syphilis treatment, the main message is practical: do not delay testing, prenatal care, or follow-up because of shortage concerns.

According to the FDA and CDC, Bicillin L-A remains the preferred treatment for syphilis. In pregnancy, penicillin is especially important because it is the only recommended treatment to help prevent congenital syphilis, which happens when the infection passes to a baby during pregnancy.

What changed in March 2026

The FDA said it would allow temporary importation of Lentocilin as a shortage response. This is a federally managed supply measure meant to help fill gaps while the Bicillin L-A shortage continues. It is not a sign that syphilis treatment standards have changed, and it does not mean the shortage is over everywhere.

In real life, that means clinics, hospitals, pharmacies, and health departments may still have uneven access for a while. Some areas may get product sooner than others. Patients should not assume the medication is immediately available at every location.

Why Bicillin L-A matters

Bicillin L-A is a long-acting injectable form of penicillin. The CDC continues to list it as first-line treatment for syphilis. That matters most in pregnancy, because other options that may be considered in some nonpregnant adults are not considered adequate substitutes for preventing congenital syphilis.

This is one reason health officials are focusing so heavily on keeping penicillin available for pregnant patients. Treating syphilis promptly during pregnancy can reduce the risk of miscarriage, stillbirth, premature birth, newborn infection, and other serious complications.

Who is being prioritized

The CDC says available Bicillin L-A supply should be prioritized for pregnant patients and for infants or babies at risk of congenital syphilis. That guidance reflects both the seriousness of congenital infection and the limited treatment options in pregnancy.

For pregnant readers, the takeaway is simple: keep prenatal appointments, get recommended syphilis testing, and do not put off care because you have heard about shortages. The American College of Obstetricians and Gynecologists recommends syphilis screening early in pregnancy, and some patients may need repeat testing later depending on risk and local requirements.

A recent study in JAMA Health Forum adds context here. It looked at prenatal syphilis screening mandate policies, not treatment itself, and helps show why timely testing matters. Policy is only one piece of the picture, but the larger point is clear: finding infection early gives clinicians more time to act.

What may happen for other adults

For some nonpregnant adults, clinicians may consider other recommended regimens if Bicillin L-A is not available. But that decision depends on the stage of syphilis, the person’s medical history, whether they can return for follow-up, and other clinical factors.

That is why this shortage is not something people should try to manage on their own. Do not switch medicines, delay treatment, or try to track down imported medication without guidance from a clinician or public health program. Syphilis treatment plans are not one-size-fits-all.

If your clinician mentions the shortage, it is reasonable to ask:

Is Bicillin L-A recommended for my situation?
If not available here, where can I get treated locally?
Is an alternative recommended for me, or should I be referred elsewhere?
When do I need follow-up testing or another visit?

Why testing still should not wait

A drug shortage can slow logistics, but it should not stop diagnosis. Early diagnosis still matters because syphilis can be easier to treat before complications develop, and because untreated infection can spread to sexual partners. During pregnancy, every delay can matter more because the infection can harm the developing baby.

Many people with syphilis may not notice symptoms right away. Others may have sores, a rash, swollen lymph nodes, fever, or other signs that can be mistaken for something else. If you think you were exposed, have symptoms, or are pregnant and due for screening, getting tested is still the right next step.

What remains uncertain

The biggest unknown for patients is local availability. Federal action may improve supply, but it does not guarantee the same access in every community at the same time. How quickly Lentocilin reaches care settings, and where it is used, may vary.

There can also be differences between hospitals, outpatient clinics, retail pharmacies, and sexually transmitted infection programs run by local or state health departments. In some places, your usual clinic may need to coordinate with another facility to arrange treatment.

What this means for readers

The shortage is ongoing, but people should not read that as a reason to avoid care. If you may have been exposed to syphilis, get tested. If you are pregnant, keep prenatal visits and ask whether you need screening now or again later in pregnancy. If a shortage affects your clinic, ask what treatment is recommended for your situation and where it is available locally.

The most important point has not changed: penicillin treatment remains especially important in pregnancy, and early testing and follow-up still matter even during a shortage.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.